HPK1-IN-2

Cat. No.:	HY-132150
CAS No.:	2056122-11-1
Molecular Formula:	$C_{19}H_{20}N_6OS$
Molecular Weight:	380.47
Target:	MAP4K; FLT3; Src
Pathway:	MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HPK1-IN-2 is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC_{50}<0.05 μM) with antitumor activity. HPK1-IN-2 also inhibits Lck (0.05 μM<IC_{50}<0.5 μM) and Flt3 (IC_{50}<0.05 μM) kinase activities[1].
IC_{50} & Target	IC50: <0.05 μM (HPK1); <0.05 μM (Flt3); 0.05-0.5 μM (Lck)[1]
In Vitro	In a-CD3 stimulated Jurkat E6. 1 cells, HPK1-IN-2 (example A1) inhibits SLP76 serine 376 phosphorylation and ERK1/2 T202/Y204 phosphorylation with IC_{50} values of 0.3-1 μM and >3μM, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	HPK1-IN-2 (example A1; 75-150 mg/kg; oral gavage; daily; for 21 days) treatment shows a dose-dependently tumor growth inhibition, with 75 mg/kg and 150 mg/kg QD inhibiting tumour growth by 44% and 64%, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice (6-8week old) injected with CT26 cancer cells[1]
Dosage:	75 mg/kg and 150 mg/kg
Administration:	Oral gavage; daily; for 21 days
Result:	Showed a dose-dependently tumor growth inhibition.

REFERENCES

[1]. Peter Brent Sampson, et al. Hpk1 inhibitors and methods of using same. WO2016205942A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA